BACKGROUND: The efficacy of intraoperative corticosteroids to improve outcomes following congenital cardiac operations remains controversial. OBJECTIVES: The purpose of this study was to determine whether intraoperative methylprednisolone improves post-operative recovery in neonates undergoing cardiac surgery. METHODS:Neonates undergoing cardiac surgery with cardiopulmonary bypass at 2 centers were enrolled in a double-blind randomized controlled trial of methylprednisolone (30 mg/kg) or placebo after the induction of anesthesia. The primary outcome was a previously validated morbidity-mortality composite that included any of the following events following surgery before discharge: death, mechanical circulatory support, cardiac arrest, hepatic injury, renal injury, or rising lactate level (>5 mmol/l). RESULTS: Of the 190 subjects enrolled, 176 (n = 81 methylprednisolone, n = 95 placebo) were included in this analysis. A total of 27 (33%) subjects in the methylprednisolone group and 40 (42%) in the placebo group reached the primary study endpoint (odds ratio [OR]: 0.63; 95% confidence interval [CI]: 0.31 to 1.3; p = 0.21). Methylprednisolone was associated with reductions in vasoactive inotropic requirements and in the incidence of the composite endpoint in subjects undergoing palliative operations (OR: 0.38; 95% CI: 0.15 to 0.99; p = 0.048). There was a significant interaction between treatment effect and center. In this analysis, methylprednisolone was protective at 1 center, with an OR: 0.35 (95% CI: 0.15 to 0.84; p = 0.02), and not so at the other center, with OR: 5.13 (95% CI: 0.85 to 30.90; p = 0.07). CONCLUSIONS:Intraoperative methylprednisolone failed to show an overall significant benefit on the incidence of the composite primary study endpoint. There was, however, a benefit in patients undergoing palliative procedures and a significant interaction between treatment effect and center, suggesting that there may be center or patient characteristics that make prophylactic methylprednisolone beneficial.
RCT Entities:
BACKGROUND: The efficacy of intraoperative corticosteroids to improve outcomes following congenital cardiac operations remains controversial. OBJECTIVES: The purpose of this study was to determine whether intraoperative methylprednisolone improves post-operative recovery in neonates undergoing cardiac surgery. METHODS: Neonates undergoing cardiac surgery with cardiopulmonary bypass at 2 centers were enrolled in a double-blind randomized controlled trial of methylprednisolone (30 mg/kg) or placebo after the induction of anesthesia. The primary outcome was a previously validated morbidity-mortality composite that included any of the following events following surgery before discharge: death, mechanical circulatory support, cardiac arrest, hepatic injury, renal injury, or rising lactate level (>5 mmol/l). RESULTS: Of the 190 subjects enrolled, 176 (n = 81 methylprednisolone, n = 95 placebo) were included in this analysis. A total of 27 (33%) subjects in the methylprednisolone group and 40 (42%) in the placebo group reached the primary study endpoint (odds ratio [OR]: 0.63; 95% confidence interval [CI]: 0.31 to 1.3; p = 0.21). Methylprednisolone was associated with reductions in vasoactive inotropic requirements and in the incidence of the composite endpoint in subjects undergoing palliative operations (OR: 0.38; 95% CI: 0.15 to 0.99; p = 0.048). There was a significant interaction between treatment effect and center. In this analysis, methylprednisolone was protective at 1 center, with an OR: 0.35 (95% CI: 0.15 to 0.84; p = 0.02), and not so at the other center, with OR: 5.13 (95% CI: 0.85 to 30.90; p = 0.07). CONCLUSIONS: Intraoperative methylprednisolone failed to show an overall significant benefit on the incidence of the composite primary study endpoint. There was, however, a benefit in patients undergoing palliative procedures and a significant interaction between treatment effect and center, suggesting that there may be center or patient characteristics that make prophylactic methylprednisolone beneficial.
Authors: Sara K Pasquali; Matthew Hall; Jennifer S Li; Eric D Peterson; James Jaggers; Andrew J Lodge; Bradley S Marino; Denise M Goodman; Samir S Shah Journal: Circulation Date: 2010-11-08 Impact factor: 29.690
Authors: Timothy M Hoffman; Gil Wernovsky; Andrew M Atz; Thomas J Kulik; David P Nelson; Anthony C Chang; James M Bailey; Akbar Akbary; John F Kocsis; Raymond Kaczmarek; Thomas L Spray; David L Wessel Journal: Circulation Date: 2003-02-25 Impact factor: 29.690
Authors: Valerie A Schroeder; Jeffery M Pearl; Steven M Schwartz; Thomas P Shanley; Peter B Manning; David P Nelson Journal: Circulation Date: 2003-05-19 Impact factor: 29.690
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Kevin D Hill; H Scott Baldwin; David P Bichel; Alicia M Ellis; Eric M Graham; Christoph P Hornik; Jeffrey P Jacobs; Robert D B Jaquiss; Marshall L Jacobs; Prince J Kannankeril; Jennifer S Li; Rachel Torok; Joseph W Turek; Sean M O'Brien Journal: Am Heart J Date: 2020-05-20 Impact factor: 4.749
Authors: Jef Van den Eynde; Nicolas Cloet; Robin Van Lerberghe; Michel Pompeu B O Sá; Dirk Vlasselaers; Jaan Toelen; Jan Y Verbakel; Werner Budts; Marc Gewillig; Shelby Kutty; Hans Pottel; Djalila Mekahli Journal: Clin J Am Soc Nephrol Date: 2021-10 Impact factor: 10.614
Authors: Laura E Murray; Holly Burchett; Shahryar M Chowdhury; A Lauren Haney; Marc Hassid; Jacob R Strelow; Eric M Graham; Minoo N Kavarana; Jason R Buckley Journal: Pediatr Cardiol Date: 2021-09-14 Impact factor: 1.838
Authors: Ben Gibbison; José Carlos Villalobos Lizardi; Karla Isis Avilés Martínez; Daniel P Fudulu; Miguel Angel Medina Andrade; Giordano Pérez-Gaxiola; Alvin Wl Schadenberg; Serban C Stoica; Stafford L Lightman; Gianni D Angelini; Barnaby C Reeves Journal: Cochrane Database Syst Rev Date: 2020-10-12